Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Indonesia Energy Corporation Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Indonesia Energy Corporation Limited trades at $2.76 (market cap $42.16M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 946.2× Indonesia Energy Corporation Limited's market cap. Which is the better fit depends on your goals.
| ALNY | INDO | |
|---|---|---|
Market Cap | $39.89B | $42.16M |
Sector | Health | Energy |
52-Week High | $491.22 | $6.74 |
52-Week Low | $278.09 | $2.49 |
Enterprise Value | $38.15B | $37.53M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
INDO trades at $2.74, down 0.72% today, with a neutral technical signal. The company shows negative profitability with a net income margin of -253.4% and a P/S ratio of 19.96, indicating high valuation relative to sales. Recent news highlights operational progress, including the commencement of drilling at the Kruh Block, which could drive future revenue growth. Analyst consensus is unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of new well operations to improve financials. Risks include persistent losses and oil market volatility. Upside potential exists if production targets are met, but investors should weigh high operational risks against speculative growth prospects in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
